Market Intelligence, Clinical Progress, and High-Purity Reagents for ccRCC, VHL Disease, and Hypoxia-Related Indications.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HIF-2α transcription factor drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Functional Domain) | HIF-2α/EPAS1 PAS-bHLH Recombinant Protein (WT & Clinical Mutant Panel). High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. | View EPAS1 Products |
| Gene Delivery | EPAS1 Promise-ORF / Lentivirus. Full-length ORF for stable reporter cell lines. | View EPAS1 Products |
| Benchmark Antibody | Anti-HIF-2α Recombinant Antibody (Research Grade). Sequence Verified; validated for WB, ELISA, ChIP. | View EPAS1 Products |
| Validator | EPAS1 Sequence-Verified siRNA Set. For knockdown verification and target engagement control. | View EPAS1 Products |
| Dimerization Partner | ARNT (HIF-1β) bHLH-PAS Domain Protein. Required for heterodimerization assays; Endotoxin <1 EU/µg. | View ARNT Products |
| Selectivity Counter-screen | HIF1A (HIF-1α) bHLH-PAS Domain Protein. Paralog specificity validation; Sequence Verified. | View HIF1A Products |
| Upstream Regulator | VHL Complex Components. E3 ubiquitin ligase targeting EPAS1; loss of function drives HIF-2α accumulation. | View VHL Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Disruption (EPAS1/ARNT) | Matched bHLH-PAS domain constructs (>95% purity, co-refolding optimized) for 1:1 stoichiometric PPI assays |
| HIF Isoform Selectivity (HIF-2α vs HIF-1α) | Human HIF1A & EPAS1 PAS-B domain proteins (>98% sequence purity, mass spec verified) for off-target liability screening |
| Drug Resistance & Mutant Profiling | Clinical mutant proteins (e.g., G323E, F87L, plus ECYT4-associated variants) with >95% purity, Sequence Verified |
| Target Engagement & DNA Binding | Full-length EPAS1 variants available; HRE DNA binding competence validated; SPR/BLI-ready |
| Lack of Controls | Benchmark antibody and validated siRNA included for specificity checks in cellular assays |
Live HIF-2α / EPAS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HIF-2α therapeutics is intensifying. Merck's Belzutifan (Welireg) is the first FDA-approved allosteric inhibitor targeting the PAS-B domain, indicated for VHL-associated ccRCC, CNS hemangioblastoma, and pNET. The next wave of R&D focuses on overcoming acquired resistance mutations (e.g., G323E, F87L) via next-generation inhibitors and PROTAC degraders, and expanding into combination regimens with immune checkpoint inhibitors and VEGF TKI. Furthermore, EPAS1 mutations are linked to familial erythrocytosis type 4 (ECYT4; e.g., variants impairing interaction with EGLN1 and VHL), highlighting the need for mutant-specific assay tools.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PAS-B Allosteric) | Merck (Belzutifan), Peloton Therapeutics, NiKang Therapeutics | VHL-RCC, ccRCC, CNS Hemangioblastoma | Heterodimer Disruption Assay (need purified EPAS1 + ARNT PAS-B proteins) |
| PROTAC Degrader | Arvinas (ARV-515), Emerging Biotechs | Refractory Solid Tumors | Whole-cell Target Engagement (need lentivirus for stable expression) |
| Isoform Selective Inhibitor | Multiple Biotechs | Polycythemia, Pulmonary Hypertension | Selectivity Assay (need EPAS1 vs HIF1A ortholog proteins) |
| Combination (IO + HIF-2αi) | Merck (Belzutifan + Pembrolizumab/Lenvatinib), Roche | Advanced RCC | Reporter Gene & Pathway Assay (need siRNA and stable cell lines) |
Key Functional Domains & Mutations
EPAS1 encodes the HIF-2α protein containing three functional domains: basic helix-loop-helix (bHLH) for DNA binding, and two PAS domains (PAS 1, PAS 2) involved in heterodimerization with ARNT and allosteric inhibitor binding. Clinically relevant mutations include those associated with ECYT4 (e.g., VAR_067358, VAR_067359, VAR_067360), which impair interaction with EGLN1 and VHL, leading to aberrant HIF-2α stabilization. These mutations require specialized recombinant proteins for functional assays.